Novavax Counting on COVID-19 Vaccine U.S. EUA by May

Novavax Chief Executive Officer Stanley Erck believes the U.S. Food and Drug Administration (FDA) could grant Emergency Use Authorization (EUA) for its COVID-19 vaccine by May.

In January, the Maryland-based company shared positive interim data from a Phase III study in the United Kingdom that shows its vaccine candidate demonstrated 89.3% efficacy against the virus.